# A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)

> **NCT01968044** · PHASE3 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 132 (actual)

## Conditions studied

- Type 2 DM Patients With Moderate or Severe Renal Impairment

## Interventions

- **DRUG:** Gemigliptin
- **DRUG:** Placebo to Linagliptin

## Key facts

- **NCT ID:** NCT01968044
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2016-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01968044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01968044, "A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01968044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*